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Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination. This leads to an
unpredictable variation in effect. Overdosing is easily recognised but it is possible that unrecognised underdosing is more
common and may occur in 30% or more of patients receiving standard regimen. Those patients who are inadvertently
underdosed are at risk of a signiﬁcantly reduced anticancer effect. Using published data, it can be calculated that there is an
almost 20% relative reduction in survival for women receiving adjuvant chemotherapy for breast cancer as a result of
unrecognised underdosing. Similarly, the cure rate of cisplatin-based chemotherapy for advanced testicular cancer may be
reduced by as much as 10%. The inaccuracy of body surface area-dosing is more than an inconvenience and it is important
that methods for more accurate dose calculation are determined, based on the known drug elimination processes for
cytotoxic chemotherapy. Twelve rules for dose calculation of chemotherapy are given that can be used as a guideline until
better dose-calculation methods become available. Consideration should be given to using ﬁxed dose guidelines independent
of body surface area and based on drug elimination capability, both as a starting dose and for dose adjustment, which may
have accuracy, safety and ﬁnancial advantages.
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Despite the recent advances in anticancer treatment and the promise
of novel targeted therapies, it is likely that cytotoxic chemotherapy
will continue to be used for the next few decades. It is now recog-
nised that our current method of dose calculation for chemotherapy
using body surface area (BSA) is inaccurate (Gurney, 1996, 1998;
Ratain, 1998). This method does not account for the marked inter-
patient variation in drug handling that is known to exist for these
drugs so that drug effects such as toxicity are also highly variable
and therefore unpredictable. One consequence is unexpected under-
dosing which leads to reduced effectiveness of chemotherapy.
However, until there is a better method, BSA-dosing will prevail
since there has been over 40 years of experience with this method
and ‘old habits die hard’. The following discussion will remind
the clinician of the inaccuracies of this system and will suggest
guidelines for dose calculation that encourages consideration of
important parameters other than BSA alone.
To calculate dose accurately drug elimination needs to be under-
stood. Typically there is a 4–10-fold variation in cytotoxic drug
clearance between individuals due to differing activity of drug elim-
ination processes related to genetic and environmental factors
(Gurney, 1996). For example, the activity of cytochrome P450
(CYP) 3A4/5, the major oxidising enzymes for many cytotoxic
drugs varies by as much as 50-fold (Wrighton et al, 1996). A
common single-nucleotide polymorphism (SNP) or CYP3A5 has
recently been identiﬁed and others are being searched for (Kuehl
et al, 2001). In addition many drugs and disease states are known
to inhibit or induce CYP activity further adding to this variation
(George et al, 1996). Another example is the eight-fold variation
in dihydropyrimidine dehydrogenase (DPD) activity, the enzyme
that catabolises 5FU (Etienne et al, 1994). Less is known about
the variation in other critical hepatic elimination processes such
as active biliary excretion by multidrug resistance gene 1
(MDR1), multidrug resistance-associated protein 2 (MRP2) and
the other ATP binding cassette (ABC) family of efﬂux pumps,
although some polymorphisms have been identiﬁed (Tanabe et
al, 2001). A number of SNPs have also recently been identiﬁed
for the steroid and xenbiotic receptor (SXR), a common-pathway
receptor which transcriptionally activates a number of the drug
elimination genes such as CYP3A4, MRP2 and MDR1 (Zhang et
al, 2001). Variation in renal function is more easily identiﬁed
but none of these complex processes are accounted for when
BSA alone is used to calculate drug dose.
THE PROBLEM OF UNDERDOSING
It is clear that for most cancers there is a plateau in the dose–
response curve for cytotoxic chemotherapy. Increasing the dose
above a standard dose will increase toxicity, but does not improve
anti-tumour effect (Gurney et al, 1993; Stadtmauer et al, 2000).
High-dose chemotherapy is now largely reserved for acute leukae-
mia and aggressive lymphomas in relapse. However, the dose
intensity studies from the last two decades have shown that anti
cancer effect is substantially reduced if the dose of drug is inten-
tionally decreased below the standard. What has not been
recognised is that a signiﬁcant proportion of patients may be inad-
vertently underdosed because of our inaccurate dose–calculation
methods, which may cause a reduced cure or other effect.
The dose of a new drug is conventionally determined in a phase
I study and then adjusted after more widespread use. The end
point of this process is prevention of toxicity rather than identify-
ing the dose for best anti-tumour effect. One consequence of this,
coupled with the inaccuracy of BSA-dosing, is that signiﬁcant
underdosing becomes intrinsic to our system of dose determina-
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www.bjcancer.comtion. Figure 1 illustrates the scheme of a phase I study for a drug
with linear pharmacokinetics. The horizontal lines represent the
variation in systemic exposure at various dose levels. At dose level
3, those patients with lower drug elimination capability develop
dose-limiting toxicity and subsequently that dose level is deﬁned
as the maximum tolerated dose. Dose level 2 is recommended
for phase II studies since it causes tolerable toxicity in all patients.
However, due to the variation in drug handling, a proportion of
patients will be relatively underdosed since they are more capable
of eliminating the drug. This means the wide distribution of
systemic exposure is skewed towards the ineffective range when
dose is calculated using BSA. Evidence for this effect can be found
in a recent study by Gaemelin et al (1999). This group had deﬁned
the optimum 5FU plasma concentration with a regimen using 5FU
in a dose of 1300 mg m
2 infused over 8 h every week. For a group
of 81 patients treated with dose calculated using BSA, 80% of
patients were found to have an ineffective 5FU plasma concentra-
tion after the ﬁrst dose.
What other evidence is available to indicate that underdosing
occurs with the current dose calculation method? Here the problem
is in deﬁning and identifying underdosing. Can the lack of effect
on normal tissue (i.e. toxicity) be used to identify a lack of effect
in neoplastic tissue? For this to be tenable a toxicity-response rela-
tionship must be shown for cytotoxic chemotherapy. There is a
wealth of information regarding dose–toxicity and dose–response
relationships but very little information is available in the literature
examining the relationship between toxicity and response (Gurney
et al, 1993). Three studies from the 1970s and 80s purport a rela-
tionship between lack of myelosuppression and lack of anti-tumour
effect in osteosarcoma and multiple myeloma (Cortes et al, 1974;
McIntyre et al, 1978; Carpenter et al, 1982). However, a ﬁrm rela-
tionship cannot be claimed given the low patient numbers and the
technique of analysis of these studies.
More recently, some studies have illustrated a toxicity-response
relationship for breast cancer, testis cancer, ovarian cancer and
lymphoma (Table 1) (Rankin et al, 1992; Horwich et al, 1997;
Poikenen et al, 1999). A randomised MRC study of combination
chemotherapy in advanced testicular cancer showed a signiﬁcantly
higher relapse rate in patients receiving carboplatin who failed to
develop myelosuppression. There was a similar relationship shown
for patients receiving cisplatin. Relapse rate for the cisplatin
containing regimen was 11% for patients with a nadir white cell
count (WCC) of over 2.0610
9 per litre compared with 4% for
patients whose WCC fell below 2.0610
9 per litre after chemother-
apy. Although this difference was not statistically signiﬁcant,
inadvertent underdosing may be an issue for cisplatin as well as
carboplatin-containing regimen in the treatment of testicular
cancer. These studies show a signiﬁcantly worse anti-tumour effect
for those patients who failed to develop myelosuppression after
treatment compared to those who did. It is important that this
relationship is examined more fully in other cancer types. This
can be done by re-analysis of previous studies where nadir blood
counts have been recorded in the majority of patients. A recent
randomised study by the Australian Lymphoma and Leukaemia
Group comparing high dose cyclophosphamide, epirubicin, vincris-
tine and prednisolone (CEOP) with standard dose CEOP, showed
that those patients who did not experience a nadir neutrophil
count of 51.0610
9 per litre, had a statistically inferior progression
free survival (Gurney et al, manuscript in preparation).
If lack of myelosuppression is accepted as an indication of
underdosing, the frequency of this event can then be determined.
Table 2 is a selection of trials where the frequency and timing of
nadir blood counts have been adequately recorded. A substantial
percentage of patients (30 to 75%) receiving commonly used
chemotherapy regimen have ‘inadequate’ myelosuppression and
may be underdosed.
THE SIGNIFICANCE OF UNDERDOSING
The possible signiﬁcance of the underdosing is outlined in Table 3.
Calculation of published data from studies using adjuvant cyclo-
phosphamide, doxorubicin and 5FU (CAF) for node positive
breast cancer show that BSA-based dosing may lead to almost a
20% relative reduction in survival in this setting (Budman et al,
1998; Early Breast Cancer Trialists’ Collaborative Group, 1998;
Silber et al, 1998). This impact is equivalent to the beneﬁt from
the use of adjuvant chemotherapy in node negative breast cancer,
or the addition of paclitaxel to the CAF regimen in node positive
breast cancer. Similarly, BSA-based dosing may reduce the cure
rate of intermediate prognosis testis cancer by almost 10%
compared to a dosing method that prevents underdosing (Samson
et al, 1984; Horwich et al, 1997). Clearly, if these calculations are
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Figure 1 Hypothetical phase I study of a drug with linear pharmacoki-
netics. Horizontal bars represent interpatient variation in systemic expo-
sure. Each vertical tick mark represents an individual patient on the study.
Dose level 3 would be considered the MTD and dose level 2 would be
recommended for phase II study despite the majority of patients on that
dose level having a systemic exposure in the sub-therapeutic range.
Table 1 Relationship between myelosuppression and anticancer effect
Reference Tumour type Outcome
Carpenter et al, 1982 Stage 2 breast cancer randomised In patients with 1 to 3 nodes, a nadir WCC of 53610
9 per litre was
between melphalan or CMF signiﬁcant predictor of disease free survival in multivariate analysis
Poikonen et al, 1999 Stage 2 breast cancer treated with CMF Low nadir leukocyte associated with longer distant disease free survival.
Horwich et al, 1997 Testis cancer treated with carboplatin, Patients with nadir WCC 52610
9 per litre and or platelets590610
9 per litre
etoposide and bleomycin had lower relapse rate. 14% vs 28%, P=0.04
Rankin et al, 1992 Advanced ovarian cancer. Carboplatin Worse progression-free survival for patients who had grade 0 WCC nadir
plus chlorambucil vs carboplatin (P50.001)
Gurney et al, (unpublished) Aggressive lymphoma treated with CEOP Worse progression free survival for patients with neutrophil count nadir of
41610
9 per litre (P=0.04)
CMF=cyclophosphamide, methotrexate, 5FU. CAF=cyclophosphamide, doxorubicin, 5FU. CEOP=cyclophosphamide, epirubicin, vincristine, prednisolone.
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as of minor consequence. It is important that more accurate calcu-
lation methods are developed. Another obvious bonus of an
accurate dose calculation scheme is prevention of toxicity from
overdosing.
PREVENTION OF UNDERDOSING
One popular method of dose individualisation is to adjust subse-
quent doses of chemotherapy based on the level of
myelosuppression eventually avoiding overdosing and underdosing
– so called ‘toxicity-adjusting dosing’ (Gurney, 1996). A Swedish
group has adopted this approach in the adjuvant treatment of breast
cancer (Berch et al, 2000). Using the 5FU, epirubicin and cyclopho-
sphamide (FEC) regimen, dose adjustments were made on each cycle
to ensure a target level of myelosuppression. After a number of dose
adjustments this method of individualising dose gave a three-fold
interpatient range of cyclophosphamide dose (450 to 1800 mg m
2)
and a four-fold range for epirubicin (38 to 120 mg m
2). This is more
in keeping with the known interpatient variation in drug clearance
for these drugs. However, it would be better to achieve an individua-
lised dose variation from the ﬁrst dose rather than the third, fourth
or ﬁfth dose. To achieve this, the dose calculation method must take
into account the activity of the elimination processes for the drug(s)
in question before the ﬁrst treatment is given.
FIXED DOSE?
Until better dose calculation methods are determined most clinicians
will continue with the traditional method using BSA. However, clin-
icians should be mindful of the inaccuracies of this system and should
not be duped by its pseudo-scientiﬁc use of formulas and slide rules.
Doses should be rounded liberally. Fractional doses are irrelevant and
unnecessary. Furthermore they are expensive and possibly unsafe. It
is unreasonable to use a small portion of an extra vial of chemother-
apy if the dose prescribe is inaccurate 40% of the time. Ask your
pharmacist whether he/she can really draw up 215 mg of DTIC
(instead of 200 or 220 mg), 85 mg of docetaxel (instead of 80 or
90 mg) or 63 mg of methotrexate. What is the additional cost of
prescribing 305 mg of paclitaxel instead of 300 mg?
Consideration should be given to using a range of ‘ﬁxed doses’
for a particular drug that could be used as the starting dose and for
dose adjustments. Remember that drug elimination varies by at
least four-fold between individuals. Can a clinically signiﬁcant
different pharmacodynamic effect be expected between 650 and
700 mg of 5FU? This probably holds true even for carboplatin
where doses are determined as a function of glomerular ﬁltration
rate. There is still a margin of error in these calculations so dose
rounding is also tenable in this situation. The alternative of using
a ﬁxed dose for chemotherapy has recently been suggested for
cisplatin and irinotecan after investigators found no relationship
between BSA and clearance for both of these drugs (de Jongh et
al, 2001; Mathijssen et al, 2002).
GUIDELINES
Guidelines for dose calculation are listed in Table 4 and an exam-
ple in Table 5. These are not comprehensive and should be used in
conjunction with clinical experience and good clinical practice.
Some of them are subjective and based on opinion and derived
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Table 2 Lack of myelosuppression from standard chemotherapy regimen
Reference Tumour type Nadir myelosuppression
Horwich et al, 1997 Testis cancer treated with carboplatin or cistaplatin and etoposide, 7% of BEP and 65 % of CEB had nadir WCC42.0610
9 per litre
bleomycin
Rankin et al, 1992 Carboplatin (dosed on BSA) with or witout chlorambucil 29.4% of patients had nadir WCC44610
9 per litre
for advanced ovarian cancer
Budman et al, 1998 Adjuvant CAF for breast cancer 44% of patients had nadir WCC42.0610
9 per litre
Silber et al, 1998 Adjuvant CAF or CMF for breast cancer 50% had nadir neutrophil count41.0610
9 per litre
Bishop et al, 1999 Advanced breast cancer treated with CMF or paclitaxel 37% had nadir neutrophil count41.5610
9 per litre
Ratain et al, 1991 Randomised study of standard vs individualised 60% of patients on standard arm had
dose of etoposide by 72 h infusion nadir WCC of 42.0610
9 per litre
Hovgaard and Nissen, 1992 CHOP for lymphoma. 127 historical controls. 50% of patients had nadir WCC42.0610
9 per litre
CMF=cyclophosphamide, methotrexate, 5FU. CAF=cyclophosphamide, doxorubicin, 5FU. BEP= bleomycin, etoposide, cisplatin. CEB=carboplatin, etoposide, bleomycin.
CHOP=cyclophosphamide, doxorubicin, vincristine, prednisolone.
Table 3
Impact of inadverent underdosing on adjuvant chemotherapy for stage 2 breast cancer
1. Halving the dose of CAF causes a reduction in the 5-year survival from 79 to 72% (absolute reduction=7%) (Budman et al, 1998)
2. In 50% of patients receiving CAF as adjuvant treatment for breast cancer, the nadir neutrophiil count will not fall below 1.0610
9 per litre. (Silber et al, 1998)
3. There is an absolute survival beneﬁt of 12% for patients less than age of 50 years receiving chemotherapy for node positive breast cancer (Early Breast Cancer
Trialists’ Collaborative Group, 1998)
If (conservatively) 30% of patients receiving CAF for stage 2 breast cancer are underdosed because of conventional dosing, absolute reduction in 5-year survival may
be 30 of 7%=2.1%, which is a 17.5% relative reduction in survival.
Impact of inadverent underdosing on chemotherapy for advanced testis cancer
1. A signiﬁcant reduction in the cisplatin dose (120 to 75mgm
72) in the PVB regimen causes a reduction un the 3-year survival from 84 to 60% (absolute
reduction=24%) (Samson et al, 1984)
2. In 75% of patients receiving BEP for treatment of advanced testis cancer, the nadir white cell will not fall below 2.0610
9 per litre. (Horwich et al, 1997)
3. The disease-free survival for BEP is 80% at 5 year (intermediate prognosis) (International Germ Cell Consensus Classiﬁcation, 1997)
If (conservatively) 30% of patients receiving chemotherapy for advanced testis cancer are underdosed because of conventional dosing, reduction in long term disease
free survival may be 30 of 24%=7.2%, which is a 9% relative reduction in cure rate.
Chemotherapy dose calculation
H Gurney
1299
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1297–1302from clinical practice while others are based on best evidence as
reviewed in Gurney (1996). The guidelines allow a framework in
which to work, in an area currently fraught with uncertainty. As
other methods of dose calculation become available, they can be
tested against these guidelines and adopted into clinical practice
if found to be superior.
As yet there are no useful in vivo measures of drug elimination
that can be used for dose calculation. Efforts have been aimed at
predicting alteration in drug elimination in those with grossly
abnormal liver or renal function with limited success. Carboplatin
can be fairly accurately dosed by measuring the GFR. Guidelines
exist for dose adjustment of other cytotoxic drugs that are predo-
minantly renally excreted (Kintzel and Dorr, 1995). However, most
cytotoxic drugs are largely hepatically eliminated. Attempts at using
elevation of serum transaminases and alkaline phosphatase as a
guide to dose adjustment have largely failed except perhaps for
docetaxel (Alexandre et al, 2000).
Potential drug interactions is an extensive problem and
warrants a separate review. Drug elimination can be enhanced
by activation of the steroid xenobiotic receptor (SXR) and other
nuclear receptors (Synold et al, 2001; Kast et al, 2002). SXR has
multiple ligands including rifampicin, dexamethasone, cyproterone
acetate, spirinolactone, St John’s wort and others. SXR activation
leads to upregulation of transcription of many elimination path-
ways including CYP3A4/5, 2B6, 2C8, MDR1, MRP2 and
glutathione-s-transferase. Inhibition of CYP enzymes and MDR1
and probably other efﬂux pumps can occur with drugs such as
cyclosporin, HMGCoA reductase inhibitors, verapamil, omepra-
zole and cimetidine. However, few clinically signiﬁcant
interactions have been documented or examined for cytotoxic
chemotherapy. Anti-convulsant induction of CYP3A4 (phenytoin,
phenobarbitone, carbemazepine) has been shown to affect the
pharmacodynamics of paclitaxel, irinotecan and tenipisode and
concomitant administration of anti-convulsants with chemother-
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Table 4 Twelve rules for dose calculation of cytotoxic chemotherapy
1. BSA-calculated dose is inaccurate. Do not use this as the sole parameter for dose calculation.
2. Do not use extremes of BSA to calculate dose (e.g.51.5 and 42.0). The use of ideal body weight has no scientiﬁc basis. However, the presence of cachexia or
obesity both affect drug handling.
3. Use BSA as a means to learn the typical absolute dose range of drugs for a particular protocol (e.g. a typical doxorubicin dose is 80 to 120mg, not 60 mg m
72).
The best dose is likely to be in that range and independent of BSA
4. Round the calculated dose liberally. Do not order ‘fractional’ dose size. e.g. 102mg of doxorubicin should be 100, 67mg of methotrexate should be 65 or 70mg.
This has safety, compounding and ﬁnancial implication.
5. Always take parameters other than BSA into consideration when calculating dose (see points 6–9).
6. Know how the drug is eliminated. If you do not know, don’t order the drug. Adjust the dose based on the appropriate tests of drug elimination e.g. serum
creatinine, GFR, bilirubin, transaminases, or other speciﬁc tests of drug elimination as they become available (genotype, phenotype).
7. Check for other medications that may inhibit or enhance cytotoxic drug elimination (see Table 6).
8. Check for other parameters that affect drug disposition e.g. serum albumin, presence of ascites, cachexia, obesity, performance status.
9. Check for other factors that affect normal tissue sensitivity that may require dose reduction e.g. prior chemotherapy and radiotherapy, performance status,
cachexia.
10. Know that this dose will be incorrect in up to 40% of the time. Approximately 10% of patients will be overdosed and 30% of patients will be underdosed.
11. Measure a biological endpoint such as myelosuppression to check affect of the administered dose. Adjust the subsequent dose UP as well as down
accordingly. A suggested minimal neutrophil count nadir for myelosuppressive drugs is 1.5610
9 per litre. Adjust all drugs in a regimen that have similar
elimination routes (e.g. doxorubicin, vinca alkaloids, podophyllotoxins, irinotecan, taxanes).
12. Always have your dose calculation checked by someone else e.g. pharmacist or nurse.
Table 5 Case example
A 45 year old woman with metastatic breast cancer to liver and bone presents for chemotherapy and you are asked to order the treatment. It has been decided that a
combination of doxorubicin and cyclophosphamide will be used. Her height is 160cm and weight 92kg. Using the Dubois formula, her body surface area is 1.95m
2. The
protocol dose is doxorubicin 60mgm
72 and cyclophosphamide 600mgm
72. Her FBC is normal.
How will you calculate the dose of chemotherapy? Is there any further information you need?
1. Both drugs are eliminated by the liver. You want to know that the liver functions tests are not grossly abnormal
2. You want to know whether she is taking any other medications that may interfere with drug elimination (seeTable 6).
3. You want to know whether she has previously received chemotherapy or extensive radiotherapy since this may affect the bone marrow response to treatment.
This is the patient’s ﬁrst dose of chemotherapy and she had radiotherapy to the breast after lumpectomy 2 years ago. Her liver functions tests are only mildly abnormal.
She is on no other medications.
Initial calculation according to the protocol gives a doxorubicin dose of 117mg and cyclophosphamide 1170mg. What dose will you give? What factors affect your decision?
1. This patient is probably obese given her height and weight. It is known that drug clearance of both drugs is reduced in obese patients.
2. You know that BSA-dose calculation is inaccurate.
3. You know that doxorubicin comes in 50mg ampoules and cyclophosphamide comes in 200mg ampoule.
4. You know that giving fractional doses are difﬁcult to compound accurately and can lead to unnecessary costs.
You decide to give a dose of doxorubicin 100mg and cyclophosphamide 1000mg.
What about subsequent doses?
You monitor the toxicity of the patient using neutropenia as a surrogate pharmacodynamic marker. You dose-reduce according to standard practice in the case of excessive
toxixity. However, you also check for the absence of toxicity since you do not want the patient to be underdosed.
The patient has minimal toxicity. A nadir FBC shows a neutrophil count of 2.5610
9 per litre and platelets of 180610
9 per litre (no signiﬁcant drop from pre-treatment level).
You increase the dose for cycle 2 by 15–20% with appropriate rounding of dose (doxorubicin 120mg, cyclophosphamide 1200mg). You plan to check the nadir blood count
after cycle 2.
Chemotherapy dose calculation
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dren with acute lymphoblastic leukaemia (Chang et al, 1998;
Friedman et al, 1999; Relling et al, 2000). Table 6 lists commonly
used drugs which may interfere with cytotoxic drug elimination,
focusing on the CYP3A4/MDR1 axis since this is the major elim-
ination route for most cytotoxic drugs and the site of most
potential drug interactions.
THE FUTURE
Studies are underway to deﬁne the drug handling genotype and
phenotype before drug administration so an individualised dose
can be given on the ﬁrst cycle (Gurney et al, 1998, 2001; Kuehl
et al, 2001; Tanabe et al, 2001; Schott et al, 2001; Zhang et al,
2001). Assessment of both hepatic metabolism and active biliary
excretion is essential since these are the important elimination
processes for the majority of cytotoxic drugs. Such in vivo tests
of drug handling would have the advantage of being applicable
to a range of cytotoxic and non-cytotoxic drugs, cleared by similar
mechanisms.
One scenario is that the majority of patients who have
‘normal’ drug elimination receive a standard ﬁxed dose of
drug according to the regimen. Pretreatment in vivo tests of
genotype or phenotype will identify the estimated 20 to
30% of patients who fall into the extremes of drug elimina-
tion capability. These patients will receive signiﬁcantly lower
or higher ﬁxed doses. In other words, starting doses will be
a range of ﬁxed doses according to low, normal or high drug
elimination. Fine-tuning of doses will be based on the
presence or absence of toxicity or some other parameter that
measures biological effect.
BSA-dosing can no longer be viewed as an inaccuracy causing
minor inconvenience in treatment of cancer patients. We have
the means to solve this problem and it is important that we do
so swiftly. Identiﬁcation of drug handling capability before treat-
ment can allow the abandonment of BSA-dosing and avoid
serious but often unrecognised underdosing.
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